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Psirelax is an herbal topical medication indicated for the treatment of 
patients with psoriasis. Its efficacy was determined in an open-label 
study in 22 patients (15 men, 7 women) with a mean age of 48.9±11.8 
years suffering from chronic plaque psoriasis. The patients were 
treated by application of Psirelax twice a day for a period of 4 weeks. 
Clinical assessment was performed using the Psoriasis Area and 
Severity Index (PASI) and the Beer-Sheva Psoriasis Severity Score 
(BPSS). The results shows that Psirelax was well tolerated and there 
no local or systemic side effects. There was 59% reduction in PASI, 
from a mean of 5.9 ± 4.0 before treatment to 2.4 ± 2.4 after treatment 
(p<0.001). In 8 patients (36%) PASI decreased in more than 75% 
(PASI75). In 16 patients (73%) PASI decreased in more than 50% 
(PASI50). Application of Psirelax was associated with a decrease in 
disease severity, as assessed by the patients and physicians. It is 
concluded that Psirelax treatment was well tolerated in patients with 
chronic plaque psoriasis.  
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INTRODUCTION 
Psoriasis is a chronic disorder which occurs in 2% of the general 
population. Patients with psoriasis have decreased quality of life 
and high rates of depression. Patients with mild to moderate 
psoriasis are usually treated with topical medications whereas 
systemic therapy is usually reserved to patients with moderate to 
severe disease. 
 
In recent years, complementary and alternative medicine has been 
used by patients with psoriasis. In a study from Israel, Ben-Arye et 
al., (2003) showed that many patients with psoriasis use herbal 
treatments. 
 
Psirelax is herbal topical medication indicated for the treatment of 
patients with psoriasis. The formulation includes natural 
ingredients such as  quince seeds jelly, base cream, anti-oxidants 
(e.g. palm tree oil, wheat germ oil), skin softening agents (e.g. 
sweet almond oil), absorption aids (e.g. jojoba oil), tissue 
regenerating and protecting agents (e.g. grape seed oil), 
preservatives (e.g. paraben) and thickening agents (e.g. bee wax).  
Preliminary uncontrolled observations have shown a beneficial 
effect of Psirelax in some patients with psoriasis. The primary 
objective of this study was to determine the efficacy of Psirelax 
topical treatment in patients with chronic plaque psoriasis. 
 
MATERIALS AND METHODS 
This was an open-label study to evaluate the tolerability of Psirelax 
treatment. Approval for the study was obtained from an institutional 
review board and written informed consent was obtained from 
each patient prior to enrolment into the study. The study was 
conducted in accordance with the ethical principles outlined in the 
Declaration of Helsinki and GCP guidelines. 
 
Population: The study included men and women between 18 and 
75 years old with a clinical diagnosis of psoriasis. All patients were 
in good general health and were free of any disease or physical 
condition which might have impaired the evaluation of plaque 
psoriasis. Excluded from the study were women who were 
pregnant, lactating, planning to become pregnant or women of 
child-bearing potential who have not successfully been using the 
same medically acceptable contraceptive methods over the 
previous 3 months, patients who used topical anti psoriatic therapy 
on the areas to be treated within one week prior to the beginning of 
the study, patients who received systemic biologic therapy to treat 
psoriasis within 12 weeks prior to the beginning of the study, 
patients who received systemic psoriasis therapy within 4 weeks 
prior to the beginning of the study, patients who received 
phototherapy within 4 weeks prior to the beginning of the study, 
patients with a recent history (within past 12 months) of alcohol or 
substance abuse, patients with a history of noncompliance to 
medical regimens and patients who had serious or unstable 
medical or psychological conditions that in the opinion of the 
Investigator could compromise the subject’s safety or successful 
participation in the study. 
 
Treatment: Psirelax is herbal topical medication indicated for the 
treatment of patients with psoriasis. Psirelax includes the following 
ingredients: 5%-15% quince seeds jelly, 10%-40% natural base 
cream (e.g. bee wax, cera alba), 55%-75% mixture of natural anti-
oxidants (e.g. vitamin E, wheat germ oil, safflower oil), natural skin 
softening agents (e.g. sweet almond oil, sesame oil), natural 
absorption aids (e.g. jojoba oil, vegetable squalene), natural tissue 
regenerating and protecting agents (e.g. grape seed oil, sunflower 
oil), natural preservatives (e.g. paraben, tea trea essential oil, 
thyme essential oil, grapefruit seed extract, vitamin E) and natural 
thickening agents (e.g. alovera, medicinal vaseline, coconut oil, 
guar gum, palm tree oil). 
 
Study design: The study was designed as an open-label study 
and included efficacy and safety assessments at weeks 2 and 4 
after enrollment in the study. 
. 
Efficacy assessments: Clinical response was measured using 
psoriasis area and severity index (PASI) and the Beer-Sheva 
Psoriasis Severity Score (BPSS). The PASI ranges from 0 to 72 
and is based on an equation that combines the percentage of 
affected body surface area (BSA) with an assessment of the extent 
and severity (erythema, desquamation and induration) of the 
psoriatic lesions at four anatomic sites (head, upper extremities, 
trunk and lower extremities).  
 
In addition to the PASI, the BPSS was also used. This is a novel 
tool for the ambulatory assessment of patients with psoriasis which 
has been described previously (Cohen et al., 2005; Cohen et al., 
2007; Cohen, et al., 2008). In the current study BPSS version IIB 
was used which has a total number of 21 items, 12 patient's items 
(with 6 scale marks within the patient's categories: 0-5), 9 
physician's items (with 5 scale marks within the physician's 
categories: 0-4). The score of BPSS, version IIB is the sum of the 
patient's items and physician's items and ranges between 0–96. 
The percent of score assessed by the patient is 62.5% as 
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Additional objective of this study was an assessment of the 
tolerability of Psirelax which was achieved by assessing local and 
systemic side effects at each visit.  
 
Sample Size Calculation: A calculation assuming a 40% 
response rate in patients treated with Psirelax demonstrated that a 
target sample size of 20 patients is sufficient to demonstrate 
preliminary effectiveness of treatment. 
 
Statistical analyses: Safety analyses were carried out on all 
patients who received Psirelax. Analyses of efficacy measures 
were based on the intent-to-treat cohort. Descriptive statistics were 
used to summarize efficacy end-points. Results of continuous 
variables are shown as means ± SD. To analyze statistically 
significant differences in continuous parameters before and after 
treatment Wilcoxon test were used. Dichotomous variables were 
analyzed using Fisher exact tests. Logistic and linear regressions 
were used for multivariate analyses. P values ≤ .05 were 
considered statistically significant. 
 
RESULTS 
The study included 22 patients (15 men, 7 women) with a mean 
age of 48.9±11.8 years. Psirelax was well tolerated and there no  
 
 
local or systemic side effects. All patients included in the study 
completed the 4 week follow-up period. The screening process 
identified 3 other patients that were excluded from analysis for 
technical reasons.  
 
Application of Psirelax was associated with a decrease in disease 
severity, as assessed by PASI and BPSS. There was a 59% 
reduction in PASI, from a mean of 5.9 ± 4.0 before treatment to 
2.4 ± 2.4 after treatment (p=0.0001) (Table 1).  
 
The reduction in PASI was pronounced in women as compared to 
men (57% of women achieved PASI75 as compared to 26% in 
men), and showed a tendency for better results in patients younger 
then 40 years (PASI75 was 40% in patients younger than 40 
years, 36% in patients between 40-60 years and 33% in patients 
above 60 years) (Table 2).  
 
In 8 patients (36%) PASI decreased in more than 75% (PASI75). 
In 16 patients (73%) PASI decreased in more than 50% (PASI50) 
(Table 3). There was a 23% reduction in BPSS, from a mean of 
19.0 ± 9.0 before treatment to 14.7 ± 9.1 after treatment (p=0.012) 
(Table 1). 
TABLE 1. ASSESSMENT OF PSORIASIS SEVERITY BEFORE AND AFTER PSIRELAX TREATMENT,  



















TABLE 2. ASSESSMENT OF PSORIASIS SEVERITY BEFORE AND AFTER PSIRELAX TREATMENT, USING PASI  
AND THE BEER-SHEVA PSORIASIS SEVERITY SCORE (BPSS), STRATIFIED BY GENDER. 
 
 Before Psirelax treatment After Psirelax treatment p-value Mean SD Min Max Mean SD Min Max 
Men          
Patients’total score 15.6 7.9 3 30 12.5 8.3 3 28 0.197 
Physicians’total score 6.1 2.3 3 10 4.8 2.5 2 10 0.006 
BPSS 21.7 9.5 9 40 17.3 9.8 6 34 0.048 
PASI 6.5 4.3 1.8 16.1 2.8 2.7 0.6 10.4 0.001 
Women          
Patients’total score 10.3 6.9 4 21 6.4 3.1 2 12 0.307 
Physicians’total score 4 1.4 2 6 2.9 1.4 1 5 0.084 
BPSS 14.3 7.1 8 25 9.3 3.2 4 14 0.104 
PASI 4.7 3.2 1.6 10.4 1.6 1.3 0.3 3.5 0.018 
 
Patients’ assessment Before Psirelax treatment After Psirelax treatment p-value Mean SD Min Max Mean SD Min Max 
General assessment 2.05 1 1 4 1.71 1.01 0 4 0.02 
Pruritis 1.59 1.3 0 5 1.43 1.16 0 4 0.699 
Scalp involvement 1.27 1.58 0 5 1.05 1.17 0 4 0.347 
Face involvement 0.55 0.96 0 4 0.45 0.91 0 3 0.483 
Hands involvement 1.82 1.47 0 5 1.23 1.19 0 4 0.09 
Palms involvement 0.59 0.96 0 4 0.41 0.8 0 3 0.314 
Chest involvement 0.68 0.99 0 3 0.55 0.86 0 3 0.276 
Trunk involvement 0.59 1.1 0 4 0.5 0.8 0 3 0.18 
Legs involvement 2.32 1.52 0 5 1.68 1.55 0 4 0.03 
Soles involvement 1 1.41 0 4 0.55 0.74 0 2 0.205 
Nails involvement 0.86 1.2 0 4 0.64 1 0 3 0.014 
Genital involvement 0.68 1.32 0 5 0.5 1.1 0 4 0.461 
Patients’ total score 13.9 7.8 3 30 10.5 7.5 2 28 0.109 
Physians’ assessment          
General assessment 1.52 0.6 1 3 1.42 0.61 1 3 0.317 
Scalp involvement 0.41 0.73 0 3 0.18 0.5 0 2 0.059 
Face involvement 0 0 0 0 0.05 0.21 0 1 0.317 
Chest and abdomen involvement 0.41 0.67 0 2 0.29 0.46 0 1 0.317 
Back involvement 0.41 0.73 0 2 0.36 0.66 0 2 0.317 
Upper limb involvement 1.41 0.8 0 3 1.05 0.65 0 3 0.005 
Palms involvement 0.05 0.22 0 1 0.05 0.21 0 1 1 
Lower limbs involvement 1.27 0.88 0 3 1 0.82 0 3 0.014 
Soles involvement 0.05 0.21 0 1 0 0 0 0 0.001 
Physicians’ total score 5.5 2.2 2 10 4.2 2.3 1 10 0.001 
BPSS 19.4 9.3 8 40 14.7 9.1 4 34 0.012 
PASI 5.9 4 1.6 16.1 2.4 2.4 0.3 10.4 <0.001 
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TABLE 3. PERCENT OF PATIENTS WHO ACHIEVE 50% AND 75% REDUCTION IN PASI AND BPSS STRATIFIED  
ACCORDING TO AGE AND GENDER (N=22). 
 
 PASI50 PASI75 
Gender   
All 16/22 (73%) 8/22 (36%) 
Male 11/15 (73%) 4/15 (26%) 
Female 5/7 (71%) 4/7 (57%) 
Age   
All 16/22 (73%) 8/22 (36%) 
<40 yrs 3/5 (60%) 2/5 (40%) 
40-60 yrs 11/14 (78%) 5/14 (36%) 
>60 yrs 2/3 (665) 1/3 (335) 
 
DISCUSSION 
In the current study we tested the safety and efficacy of a novel 
herbal topical medication (Psirelax) for patients with chronic plaque 
psoriasis. Psirelax includes natural ingredients such as quince 
seeds, sweet almond oil, jojoba oil, grape seed oil and bee wax. 
 
The results of the study show that Psirelax was well tolerated. No 
adverse events were observed. Application of Psirelax was 
associated with a decrease in disease severity, as assessed by 
the patients and physicians. Psirelax contains a unique blend of 
natural herbal oils and seeds that have effects of oiling and 
emulsifying the skin with possible anti-inflammatory and immune 
modulating activities. 
 
Psirelax ingredients include sunflower seed oil which contains high 
levels of essential fatty acids (e.g. linoleic acid) that have skin 
barrier-enhancing properties. A sunflower oleodistillate has been 
shown to increase the epidermal key lipid synthesis and to reduce 
inflammation in vitro and in animal models. Sunflower oleodistillate 
has been shown to activate peroxisome proliferative-activated 
receptor-alpha in vitro, which stimulates keratinocyte 
differentiation, improve barrier function, and enhance lipid 
metabolism in the skin. Some studies have shown the efficacy of 
sunflower seed oil in atopic dermatitis (Eichenfield et al., 2009).  
 
Complementary medicine includes therapeutic modalities that 
derive from traditional and philosophical systems of medicine, 
which view health and disease in the context of human totality of 
body and mind. The effect of Psirelax observed in our patients 
demonstrates the beneficial effect of this new complementary 
medication in patients with psoriasis. 
 
Psirelax also contains wheat germ oil was which was never 
studied in the treatment of psoriasis. A study showing 
improvement in rheumatoid arthritis patients taking wheat germ, 
proposed that a modulation of apoptosis is responsible for the 
effect (Balint et al., 2006). Other natural oils used in Psirelax 
include sweet almond oil and jojoba oil. The oil form makes these 
natural oils effective as emollient and moisturizer for human skin 
(Natural medicines comprehensive database). Sweet almond oil 
has a weak anti bacterial effect and may be used as demulcent, 
while jojoba oil has healing effects on acne, sunburn, and chapped 
skin. Small scale studies have proven that sweet almond oil and 
jojoba oil has a beneficial effect in patients with psoriasis by the 
skin’s inflammatory process. Patients treated with the oils showed 
clinical improvement after treatment (Meyer et al., 2008; Natural 
medicines comprehensive database, 2011). 
 
Quince is used topically as a compression for injuries, 
inflammation of the joints, injuries of the nipples, and skin 
lacerations. A topical lotion is used to soothe the eyes. Sweet 
almond is used topically as an emollient for chapped skin, to 
soothe mucous membranes and as a weak antibacterial (Natural 
medicines comprehensive database, 2011). Applications of 5% 
extract cream of Aloe Vera (Barbadensis) topically 3 times daily for 
4  
 
weeks significantly improved and increased the resolution of 
psoriatic plaques compared to placebo (Klein & Penneys, 1988). 
Aloe extract cream seems to reduce desquamation, erythema, 
infiltration and generate significant improvement of lesions in a 
double blind placebo controlled studies (Syed et al., 1996; Paulsen 
et al., 2005). 
 
Beeswax is used by honey bees to build their honeycomb cells. 
Beeswax provides protective effects to human skin against contact 
irritants and allergens (Zhai et al., 1998; Teichmann et al., 2006). 
The benefits of beeswax for psoriasis treatment are supported by 
the findings of Al-Waili, (2003) who studied the healing effect of the 
combination beeswax, honey, and olive oil on patients with 
psoriasis and atopic dermatitis. 
 
It is possible that the outcome of Psirelax treatment observed in 
the current study is attributed to placebo effect or to the lubrication 
affect of Psirelax formula. However, these preliminary results are 
encouraging and suggest that a double blind placebo controlled 
study should be conducted to further assess the efficacy of 
Psirelax in patients with psoriasis. 
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